ETF Managers Group’s Regeneron Pharmaceuticals REGN Stock Holding History

ETF Managers Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$355K	Sell	432 -3,449	-89%	-$2.6M	0.01%	519
2022 Q4	$2.8M	Buy	3,881 +3,587	+1,220%	+$2.65M	0.13%	93
2022 Q3	$203K	Buy	294 +7	+2%	+$4.41K	0.01%	596
2022 Q2	$172K	Sell	287 -98	-25%	-$63.7K	0.01%	660
2022 Q1	$267K	Sell	385 -214	-36%	-$135K	0.01%	558
2021 Q4	$385K	Sell	599 -145	-19%	-$89.2K	0.01%	564
2021 Q3	$451K	Buy	744 +32	+4%	+$19.9K	0.01%	547
2021 Q2	$389K	Sell	712 -94	-12%	-$47.6K	0.01%	564
2021 Q1	$379K	Buy	806 +54	+7%	+$26.3K	0.01%	552
2020 Q4	$360K	Buy	752 +121	+19%	+$65.3K	0.01%	499
2020 Q3	$362K	Buy	631 +406	+180%	+$246K	0.01%	383
2020 Q2	$137K	Buy	+225	New	+$128K	﹤0.01%	572
2016 Q1	$26K	Buy	+66	New	+$27.2K	0.02%	409

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ETF Managers Group's REGN Position: Q1 2023 in Review

ETF Managers Group reduced its Regeneron Pharmaceuticals (REGN) stake by 89% in Q1 2023, selling an estimated $2.6M and leaving 432 shares worth $355K. The position accounts for 0.01% of the portfolio, ranked #519.

ETF Managers Group first reported a position in REGN in Q1 2016 and has held it in 13 quarters since. The position peaked at $2.8M in Q4 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

ETF Managers Group held 432 shares of Regeneron Pharmaceuticals worth $355K as of Q1 2023.
ETF Managers Group sold 3,449 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $2.6M.
Regeneron Pharmaceuticals made up 0.01% of ETF Managers Group's portfolio in Q1 2023, its #519 holding.
ETF Managers Group first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 13 quarters since.
ETF Managers Group's Regeneron Pharmaceuticals position peaked at $2.8M in Q4 2022.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.